PE20170442A1 - (2s)-3-[(3s,4s)-3-[(1r)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-metilpiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol cristalino - Google Patents

(2s)-3-[(3s,4s)-3-[(1r)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-metilpiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol cristalino

Info

Publication number
PE20170442A1
PE20170442A1 PE2017000107A PE2017000107A PE20170442A1 PE 20170442 A1 PE20170442 A1 PE 20170442A1 PE 2017000107 A PE2017000107 A PE 2017000107A PE 2017000107 A PE2017000107 A PE 2017000107A PE 20170442 A1 PE20170442 A1 PE 20170442A1
Authority
PE
Peru
Prior art keywords
oxopropane
methylpyrrolidin
azetidin
methylpyridin
oxy
Prior art date
Application number
PE2017000107A
Other languages
English (en)
Inventor
Ping Huang
Seth Dietrich Ribe
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20170442A1 publication Critical patent/PE20170442A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE AL COMPUESTO (2S)-3-[(3S,4S)-3-[(1R)-1-HIDROXIETIL]-4-(4-METOXI-3-{[1-(5-METILPIRIDIN-2-IL)AZETIDIN-3-IL]OXI}FENIL)-3-METILPIRROLIDIN-1-IL]-3-OXOPROPANO-1,2-DIOL CRISTALINO, CUYO PATRON DE DIFRACCION EN POLVO DE RAYOS X EN ANGULO 2THETA TIENE LOS SIGUIENTES PICOS: 18.5°, 16.2°, 20.2° Y 14.4° ± 0.2°. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES INHIBIDOR DE FOSFODIESTERASA 4 (PDE4) SIENDO UTIL EN EL TRATAMIENTO DE VEJIGA HIPERACTIVA
PE2017000107A 2014-09-04 2015-08-28 (2s)-3-[(3s,4s)-3-[(1r)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-metilpiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol cristalino PE20170442A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/085925 WO2016033776A1 (en) 2014-09-04 2014-09-04 Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol

Publications (1)

Publication Number Publication Date
PE20170442A1 true PE20170442A1 (es) 2017-04-26

Family

ID=54073019

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000107A PE20170442A1 (es) 2014-09-04 2015-08-28 (2s)-3-[(3s,4s)-3-[(1r)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-metilpiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol cristalino

Country Status (26)

Country Link
US (1) US10065942B2 (es)
EP (1) EP3189044B1 (es)
JP (1) JP6364545B2 (es)
KR (1) KR20170038884A (es)
CN (1) CN107001327B (es)
AP (1) AP2017009774A0 (es)
AU (1) AU2015312229B2 (es)
BR (1) BR112017003010A2 (es)
CA (1) CA2956517A1 (es)
CL (1) CL2017000467A1 (es)
CO (1) CO2017001097A2 (es)
CR (1) CR20170051A (es)
DO (1) DOP2017000037A (es)
EA (1) EA031089B1 (es)
EC (1) ECSP17013015A (es)
ES (1) ES2688167T3 (es)
IL (1) IL250356A0 (es)
MA (1) MA40606A (es)
MX (1) MX2017002688A (es)
NZ (1) NZ728359A (es)
PE (1) PE20170442A1 (es)
PH (1) PH12017500400A1 (es)
SG (1) SG11201701608RA (es)
TN (1) TN2017000045A1 (es)
TW (1) TWI570119B (es)
WO (2) WO2016033776A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201625591A (zh) * 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
WO2021036953A1 (zh) * 2019-08-23 2021-03-04 湖北生物医药产业技术研究院有限公司 苯基吡咯烷类化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7585882B2 (en) * 2004-10-20 2009-09-08 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
BRPI0616633A2 (pt) 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
JO3264B1 (ar) * 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين

Also Published As

Publication number Publication date
TW201619149A (zh) 2016-06-01
SG11201701608RA (en) 2017-03-30
CN107001327B (zh) 2022-09-02
EP3189044B1 (en) 2018-08-01
JP6364545B2 (ja) 2018-07-25
US10065942B2 (en) 2018-09-04
EP3189044A1 (en) 2017-07-12
TWI570119B (zh) 2017-02-11
MA40606A (fr) 2016-03-10
CL2017000467A1 (es) 2017-10-20
ECSP17013015A (es) 2018-03-31
CA2956517A1 (en) 2016-03-10
JP2017525747A (ja) 2017-09-07
CO2017001097A2 (es) 2017-04-28
US20170233373A1 (en) 2017-08-17
WO2016036596A1 (en) 2016-03-10
WO2016033776A1 (en) 2016-03-10
EA201790143A1 (ru) 2017-06-30
MX2017002688A (es) 2017-05-30
CN107001327A (zh) 2017-08-01
PH12017500400A1 (en) 2017-07-17
BR112017003010A2 (pt) 2017-12-12
EA031089B1 (ru) 2018-11-30
IL250356A0 (en) 2017-03-30
DOP2017000037A (es) 2017-02-28
NZ728359A (en) 2018-08-31
CR20170051A (es) 2017-04-26
AU2015312229B2 (en) 2017-11-16
TN2017000045A1 (en) 2018-07-04
AP2017009774A0 (en) 2017-02-28
KR20170038884A (ko) 2017-04-07
AU2015312229A1 (en) 2017-02-02
ES2688167T3 (es) 2018-10-31

Similar Documents

Publication Publication Date Title
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CU24406B1 (es) 1-{[(2s,3s,4s)-3-etil-4-fluoro-5-oxopirrolidin-2-il]metoxi}-7 -metoxiisoquinolin-6-carboxamida
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
EA201401292A3 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
EA201790661A2 (ru) Ингибиторы вируса гепатита c
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
UY34202A (es) Compuestos fungicidas 2-(2-clor0-4-(4-cloro-fenoxi)-fenil]-1-(1,2,4]triazol-1-1l-etanol alquilo sustituidos
EA201590534A1 (ru) Новые бициклические производные
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
EA201390633A1 (ru) Новые вещества для повторно перерабатываемых эпоксидных смол
EA201491623A1 (ru) Замещенные пирролидин-2-карбоксамиды
RS54730B1 (sr) Inhibitori beta sekretaze
GEP201706725B (en) Compounds and compositions as inhibitors of mek
EA201591024A1 (ru) Димерные соединения
EA201592183A1 (ru) Ингибиторы bace
HRP20200119T1 (hr) Azetidiniloksifenilpirolidinski spojevi
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
WO2015070238A3 (en) Coumarin based hsp90 inhibitors with urea and ether substituents
HRP20170080T1 (hr) Spojevi azetidiniloksifenilpirolidina
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
PH12016500461A1 (en) Polyethylene glycol-containing composition
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы